{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:56:03Z","timestamp":1790056563131,"version":"4.0.1"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2018-0118_s_010_w2aab3b7b3b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d5788578e5236_w2aab3b7b3b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>\n                      Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) is a novel laparoscopic intraperitoneal chemotherapy technique, with advantages such as homogeneous distribution of aerosol and deeper tissue penetration. Thus far, PIPAC oxaliplatin has been administered at an arbitrary dose of 92\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0118_s_011_w2aab3b7b3b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d5788578e5248_w2aab3b7b3b1b6b1aab1c16b2aAa\">Aim<\/jats:title>\n                    <jats:p>We aim to determine the dose-related safety profile and tolerability of PIPAC oxaliplatin using an evidence-based approach. The secondary aim is to evaluate clinic-pathologic response and the pharmacokinetic profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0118_s_012_w2aab3b7b3b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d5788578e5257_w2aab3b7b3b1b6b1aab1c16b3aAa\">Methods<\/jats:title>\n                    <jats:p>\n                      This is a phase I 3+3 dose escalation study for gastric and colorectal cancer with predominant peritoneal metastasis starting at a dose of 45\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Safety is assessed according to Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (version 4.0). Clinico-pathologic response is assessed using the Peritoneal Regression Grading Score, Peritoneal Cancer Index, and Response Evaluation Criteria In Solid Tumour criteria (version 1.1). Pharmacokinetic analysis is performed using Inductively Coupled Plasma-Mass Spectrometry assay. This trial is registered on ClinicalTrials.gov (NCT03172416).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2018-0118_s_013_w2aab3b7b3b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d5788578e5269_w2aab3b7b3b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>This phase I study can provide the scientific basis to identify the optimal dose for PIPAC with oxaliplatin such that the benefits of this novel and promising intraperitoneal chemotherapy delivery technique can be maximized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2018-0118","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:55:16Z","timestamp":1535561716000},"source":"Crossref","is-referenced-by-count":27,"title":["Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis"],"prefix":"10.1515","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-6808","authenticated-orcid":false,"given":"Guowei","family":"Kim","sequence":"first","affiliation":[{"name":"University Surgical Cluster, National University Health System , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon Lyn","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elya","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery , National University of Singapore , Yong Loo Lin School of Medicine , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Chin","family":"Teo","sequence":"additional","affiliation":[{"name":"Department of Surgery , National University of Singapore , Yong Loo Lin School of Medicine , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse Jia Min","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Surgery , National University of Singapore , Yong Loo Lin School of Medicine , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Ang","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Yan Li","family":"Ngoi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Ean","family":"Chee","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Lieske","sequence":"additional","affiliation":[{"name":"University Surgical Cluster, National University Health System , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[{"name":"University Surgical Cluster, National University Health System , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Bok Yan","family":"So","sequence":"additional","affiliation":[{"name":"Department of Surgery , National University of Singapore , Yong Loo Lin School of Medicine , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology , National University Cancer Institute , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"2025120909212499951_j_pp-2018-0118_ref_001_w2aab3b7b3b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc Other Interv Tech. 2012;26:1849\u201355.","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909212499951_j_pp-2018-0118_ref_002_w2aab3b7b3b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, et\u2009al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26:847\u201352.10.1007\/s00464-011-1964-y22042585","DOI":"10.1007\/s00464-011-1964-y"},{"key":"2025120909212499951_j_pp-2018-0118_ref_003_w2aab3b7b3b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367\u20133.10.1007\/s11605-015-2995-926511950","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2025120909212499951_j_pp-2018-0118_ref_004_w2aab3b7b3b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.10.1186\/s12957-016-0892-727125996","DOI":"10.1186\/s12957-016-0892-7"},{"key":"2025120909212499951_j_pp-2018-0118_ref_005_w2aab3b7b3b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, et\u2009al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553\u201359.10.1245\/s10434-013-3213-124006094","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909212499951_j_pp-2018-0118_ref_006_w2aab3b7b3b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Demtr\u00f6der C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016;18:364\u201371.10.1111\/codi.13130","DOI":"10.1111\/codi.13130"},{"key":"2025120909212499951_j_pp-2018-0118_ref_007_w2aab3b7b3b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"H\u00fcbner M, Teixeira Farinha H, Grass F, Wolfer A, Mathevet P, Hahnloser D, et\u2009al. Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract. 2017;2017:6852749.28331493","DOI":"10.1155\/2017\/6852749"},{"key":"2025120909212499951_j_pp-2018-0118_ref_008_w2aab3b7b3b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.10.1097\/01.sla.0000133083.54934.ae","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025120909212499951_j_pp-2018-0118_ref_009_w2aab3b7b3b1b6b1ab1b5b9Aa","unstructured":"National cancer institute - common terminology criteria for adverse events (CTCAE). 2010;2009:0\u201371. Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"2025120909212499951_j_pp-2018-0118_ref_010_w2aab3b7b3b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Pestieau SR, Belliveau JI, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol. 2001;76:106\u201314.10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E11223836","DOI":"10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E"},{"key":"2025120909212499951_j_pp-2018-0118_ref_011_w2aab3b7b3b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et\u2009al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.10.1016\/j.ejca.2008.10.02619097774","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025120909212499951_j_pp-2018-0118_ref_012_w2aab3b7b3b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Sempoux C, Carr NJ. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura and Peritoneum. 2016;1:99\u2013107.30911613","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909212499951_j_pp-2018-0118_ref_013_w2aab3b7b3b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et\u2009al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.843339010.1093\/jnci\/85.5.365","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025120909212499951_j_pp-2018-0118_ref_014_w2aab3b7b3b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236\u201342.1067193410.1046\/j.1365-2168.2000.01360.x","DOI":"10.1046\/j.1365-2168.2000.01360.x"},{"key":"2025120909212499951_j_pp-2018-0118_ref_015_w2aab3b7b3b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et\u2009al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.10.1016\/S1470-2045(16)30500-927743922","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2025120909212499951_j_pp-2018-0118_ref_016_w2aab3b7b3b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et\u2009al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.10.1093\/annonc\/mdp26019605503","DOI":"10.1093\/annonc\/mdp260"},{"key":"2025120909212499951_j_pp-2018-0118_ref_017_w2aab3b7b3b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et\u2009al. The American society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779\u201385.2508830410.1002\/jso.23728","DOI":"10.1002\/jso.23728"},{"key":"2025120909212499951_j_pp-2018-0118_ref_018_w2aab3b7b3b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Kono K, Yong WP, Okayama H, Shabbir A, Momma T, Ohki S, et\u2009al. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer. 2017;20:122\u201327.2776649610.1007\/s10120-016-0660-y","DOI":"10.1007\/s10120-016-0660-y"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/3\/3\/article-20180118.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0118\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:48:02Z","timestamp":1765277282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0118\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9,25]]},"published-print":{"date-parts":[[2018,9,25]]}},"alternative-id":["10.1515\/pp-2018-0118"],"URL":"https:\/\/doi.org\/10.1515\/pp-2018-0118","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"article-number":"20180118"}}